Pancreatic cancer drug daraxonrasib touted as ‘biggest leap forward’ in decades after controlling disease in 90% of patients
Pancreatic cancer drug daraxonrasib: Daraxonrasib has emerged as a promising treatment for advanced pancreatic cancer, showing remarkable results in recent trials. Among 61 patients tested, an impressive 90.2% had their tumor growth stopped, while...

A total of 61 patients with advanced pancreatic cancer received the pancreatic cancer drug daraxonrasib in combination with chemotherapy and were followed for one and a half years during the trial. Tumors stopped growing in 90.2% of patients, while 60.7% saw their tumors shrink or disappear. Of the 61 participants, five (8.2%) achieved a complete response, meaning their tumors were no longer detectable on CT scans, the European Organization for Research and Treatment of Cancer (EORTC) said in a media release on Thursday, November 19.

In comparison, for most of the metastatic pancreatic cancer patients who were treated with standard chemotherapy, survival is between eight and eleven months, and only three percent are alive five years after diagnosis. As per the organization’s estimates, tumor shrinkage is seen in only 23%-42% of patients depending on only chemotherapy, and most tumors start to grow again after five to six months.
These findings on Pancreatic cancer drug daraxonrasib, which the US Food and Drug Administration (FDA) approved to treat metastatic pancreatic cancer in August, were presented by Dr. Wungki Park, a gastrointestinal medical oncologist from New York’s Memorial Sloan Kettering Cancer Center, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
“This is the closest to cure,” Park said during the presentation said, adding that he had never witnessed so many tumors disappear in patients whose cancer had spread, The Guardian reported.
Daraxonrasib is a KRAS inhibitor that works by binding to and switching off certain mutations found in most pancreatic cancers. These mutations drive tumor growth.
“This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers,” Cancer Research UK’s chief executive Michelle Mitchell said to the outlet in a statement.
Adding the need for more such research, he said, “More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low.”
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.